Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Payables (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Payables for 5 consecutive years, with $6.4 million as the latest value for Q1 2026.

  • For Q1 2026, Payables fell 45.21% year-over-year to $6.4 million; the TTM value through Mar 2026 reached $6.4 million, down 45.21%, while the annual FY2025 figure was $5.0 million, 52.57% down from the prior year.
  • Payables hit $6.4 million in Q1 2026 for Phathom Pharmaceuticals, up from $5.0 million in the prior quarter.
  • Across five years, Payables topped out at $12.6 million in Q4 2023 and bottomed at $1.1 million in Q3 2025.
  • Average Payables over 5 years is $6.8 million, with a median of $6.4 million recorded in 2026.
  • Year-over-year, Payables surged 83.42% in 2024 and then plummeted 84.93% in 2025.
  • Phathom Pharmaceuticals' Payables stood at $10.0 million in 2022, then rose by 26.05% to $12.6 million in 2023, then decreased by 16.62% to $10.5 million in 2024, then plummeted by 52.57% to $5.0 million in 2025, then grew by 27.73% to $6.4 million in 2026.
  • According to Business Quant data, Payables over the past three periods came in at $6.4 million, $5.0 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.